In the preceding three months, 6 analysts have released ratings for Harmony Biosciences (NASDAQ:HRMY), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Harmony Biosciences, presenting an average target of $52.0, a high estimate of $56.00, and a low estimate of $48.00. This current average has not changed from the previous average price target.
Diving into Analyst Ratings: An In-Depth Exploration
In examining recent analyst actions, we gain...
Login or create a forever free account to read this news
Sign up/Log in
